+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Vinca Alkaloid Compounds Market By Product Type: Global Opportunity Analysis and Industry Forecast, 2024-2033

  • PDF Icon

    Report

  • 280 Pages
  • July 2024
  • Region: Global
  • Allied Market Research
  • ID: 5994235
Description Jump to:
The vinca alkaloid compounds market was valued at $81.0 million in 2023 and is projected to reach $161.5 million by 2033, growing at a CAGR of 7.2% from 2024 to 2033.

Vinca alkaloid is a naturally occurring secondary metabolite, majorly extracted from the periwinkle plant Catharanthus roseus. The compound is utilized for its anti-mitotic and anti-microtubule properties. During cell division, vinca alkaloid compounds block the polymerization of beta-tubulin, a protein necessary to provide structural support during cell division. This blockage results in cytotoxicity and cell death. This property of the compounds is utilized as a therapeutic approach for the treatment of various cancers, including lymphomas, leukemias, breast cancer, and lung cancer.

Increase in the prevalence of various cancer forms and advancements in the development of therapeutic drugs are the significant drivers of the vinca alkaloid compounds market. Furthermore, constant R&D efforts toward the generation of medications and treatment solutions for the mitigation of cancer boost the demand for vinca alkaloid compounds. The synthesis of this secondary metabolite using endophytes is projected to be a significant trend in the future. Extraction of vinca alkaloid compounds directly from the plant is highly inefficient and intricate. Contrarily, the process of microbial fermentation of endophytes is a notably feasible and competent procedure, which is anticipated to facilitate and boost the production of anti-cancer drugs in upcoming years.

However, the potential side-effects of vinca alkaloid compounds are severe, including neurotoxicity and myelosuppression. This limits the usage of compounds to a certain extent, hence restraining the development of the market. Moreover, the tumor cells develop a resistance to the drugs derived from vinca alkaloid compounds over long durations, lowering their long-term efficacy and hampering the market growth. On the contrary, innovations in drug development have led to the harnessing of anti-cancerous properties of vinca alkaloid compounds by eliminating their limitations, presenting lucrative opportunities for the expansion of the market. For instance, according to a research paper published on the National Library of Medicine, the side-effects of vinca alkaloid compounds are mitigated using combination therapy, in which the compound is combined with some other chemotherapy drug, enhancing the anti-tumor effect of the cocktail drug.

Segment Review

The vinca alkaloid compounds market is segmented into product type, end user, and region. On the basis of product type, the market is divided into vinblastine, vincristine, and vindesine. As per end user, it is classified into hospitals, clinics, and academic & research institutes. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of product type, the vincristine segment dominated the market in 2023.

As per end user, the hospitals segment accounted for a high market share in 2023.

Region wise, North America was the highest revenue generator in 2023.

Competition Analysis

The leading players operating in the global vinca alkaloid compounds market include Accord Healthcare Limited, Eli Lilly and Company., Fresenius Kabi AG, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Medline Industries, LP., Pfizer Inc., Pierre Fabre S.A, Talon Pharmaceuticals, Teva Pharmaceutical Industries Limited, and Viatris Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product Type

  • Vinblastine
  • Vincristine
  • Vindesine

By End User

  • Hospitals
  • Clinics
  • Academic Research Institutes

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
Key Market Players
  • Accord Healthcare Limited
  • Eli Lilly and Company.
  • Fresenius Kabi AG
  • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  • Medline Industries, LP.
  • Pfizer Inc.
  • Pierre Fabre S.A
  • Talon Pharmaceuticals
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc.

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: VINCA ALKALOID COMPOUNDS MARKET, BY PRODUCT TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Product Type
4.2. Vinblastine
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Vincristine
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Vindesine
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
CHAPTER 5: VINCA ALKALOID COMPOUNDS MARKET, BY END USER
5.1. Market Overview
5.1.1 Market Size and Forecast, By End User
5.2. Hospitals
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Clinics
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Academic Research Institutes
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
CHAPTER 6: VINCA ALKALOID COMPOUNDS MARKET, BY REGION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Region
6.2. North America
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, By Product Type
6.2.3. Market Size and Forecast, By End User
6.2.4. Market Size and Forecast, By Country
6.2.5. U.S. Vinca Alkaloid Compounds Market
6.2.5.1. Market Size and Forecast, By Product Type
6.2.5.2. Market Size and Forecast, By End User
6.2.6. Canada Vinca Alkaloid Compounds Market
6.2.6.1. Market Size and Forecast, By Product Type
6.2.6.2. Market Size and Forecast, By End User
6.2.7. Mexico Vinca Alkaloid Compounds Market
6.2.7.1. Market Size and Forecast, By Product Type
6.2.7.2. Market Size and Forecast, By End User
6.3. Europe
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, By Product Type
6.3.3. Market Size and Forecast, By End User
6.3.4. Market Size and Forecast, By Country
6.3.5. Germany Vinca Alkaloid Compounds Market
6.3.5.1. Market Size and Forecast, By Product Type
6.3.5.2. Market Size and Forecast, By End User
6.3.6. France Vinca Alkaloid Compounds Market
6.3.6.1. Market Size and Forecast, By Product Type
6.3.6.2. Market Size and Forecast, By End User
6.3.7. UK Vinca Alkaloid Compounds Market
6.3.7.1. Market Size and Forecast, By Product Type
6.3.7.2. Market Size and Forecast, By End User
6.3.8. Italy Vinca Alkaloid Compounds Market
6.3.8.1. Market Size and Forecast, By Product Type
6.3.8.2. Market Size and Forecast, By End User
6.3.9. Spain Vinca Alkaloid Compounds Market
6.3.9.1. Market Size and Forecast, By Product Type
6.3.9.2. Market Size and Forecast, By End User
6.3.10. Rest of Europe Vinca Alkaloid Compounds Market
6.3.10.1. Market Size and Forecast, By Product Type
6.3.10.2. Market Size and Forecast, By End User
6.4. Asia-Pacific
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, By Product Type
6.4.3. Market Size and Forecast, By End User
6.4.4. Market Size and Forecast, By Country
6.4.5. Japan Vinca Alkaloid Compounds Market
6.4.5.1. Market Size and Forecast, By Product Type
6.4.5.2. Market Size and Forecast, By End User
6.4.6. China Vinca Alkaloid Compounds Market
6.4.6.1. Market Size and Forecast, By Product Type
6.4.6.2. Market Size and Forecast, By End User
6.4.7. Australia Vinca Alkaloid Compounds Market
6.4.7.1. Market Size and Forecast, By Product Type
6.4.7.2. Market Size and Forecast, By End User
6.4.8. India Vinca Alkaloid Compounds Market
6.4.8.1. Market Size and Forecast, By Product Type
6.4.8.2. Market Size and Forecast, By End User
6.4.9. South Korea Vinca Alkaloid Compounds Market
6.4.9.1. Market Size and Forecast, By Product Type
6.4.9.2. Market Size and Forecast, By End User
6.4.10. Rest of Asia-Pacific Vinca Alkaloid Compounds Market
6.4.10.1. Market Size and Forecast, By Product Type
6.4.10.2. Market Size and Forecast, By End User
6.5. LAMEA
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, By Product Type
6.5.3. Market Size and Forecast, By End User
6.5.4. Market Size and Forecast, By Country
6.5.5. Brazil Vinca Alkaloid Compounds Market
6.5.5.1. Market Size and Forecast, By Product Type
6.5.5.2. Market Size and Forecast, By End User
6.5.6. Saudi Arabia Vinca Alkaloid Compounds Market
6.5.6.1. Market Size and Forecast, By Product Type
6.5.6.2. Market Size and Forecast, By End User
6.5.7. South Africa Vinca Alkaloid Compounds Market
6.5.7.1. Market Size and Forecast, By Product Type
6.5.7.2. Market Size and Forecast, By End User
6.5.8. Rest of LAMEA Vinca Alkaloid Compounds Market
6.5.8.1. Market Size and Forecast, By Product Type
6.5.8.2. Market Size and Forecast, By End User
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. Accord Healthcare Limited
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. Eli Lilly And Company.
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Fresenius Kabi AG
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. Medline Industries, LP.
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. Pfizer Inc.
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Pierre Fabre S.A
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. Talon Pharmaceuticals
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. Teva Pharmaceutical Industries Limited
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. Viatris Inc.
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
LIST OF TABLES
Table 1. Global Vinca Alkaloid Compounds Market, by Product Type, 2024 - 2033 ($Million)
Table 2. Vinca Alkaloid Compounds Market for Vinblastine, by Region, 2024 - 2033 ($Million)
Table 3. Vinca Alkaloid Compounds Market for Vincristine, by Region, 2024 - 2033 ($Million)
Table 4. Vinca Alkaloid Compounds Market for Vindesine, by Region, 2024 - 2033 ($Million)
Table 5. Global Vinca Alkaloid Compounds Market, by End-user, 2024 - 2033 ($Million)
Table 6. Vinca Alkaloid Compounds Market for Hospitals, by Region, 2024 - 2033 ($Million)
Table 7. Vinca Alkaloid Compounds Market for Clinics, by Region, 2024 - 2033 ($Million)
Table 8. Vinca Alkaloid Compounds Market for Academic Research Institutes, by Region, 2024 - 2033 ($Million)
Table 9. Vinca Alkaloid Compounds Market, by Region, 2024 - 2033 ($Million)
Table 10. North America Vinca Alkaloid Compounds Market, by Country, 2024 - 2033 ($Million)
Table 11. North America Vinca Alkaloid Compounds Market, by Product Type, 2024 - 2033 ($Million)
Table 12. North America Vinca Alkaloid Compounds Market, by End-user, 2024 - 2033 ($Million)
Table 13. U.S. Vinca Alkaloid Compounds Market, by Product Type, 2024 - 2033 ($Million)
Table 14. U.S. Vinca Alkaloid Compounds Market, by End-user, 2024 - 2033 ($Million)
Table 15. Canada Vinca Alkaloid Compounds Market, by Product Type, 2024 - 2033 ($Million)
Table 16. Canada Vinca Alkaloid Compounds Market, by End-user, 2024 - 2033 ($Million)
Table 17. Mexico Vinca Alkaloid Compounds Market, by Product Type, 2024 - 2033 ($Million)
Table 18. Mexico Vinca Alkaloid Compounds Market, by End-user, 2024 - 2033 ($Million)
Table 19. Europe Vinca Alkaloid Compounds Market, by Country, 2024 - 2033 ($Million)
Table 20. Europe Vinca Alkaloid Compounds Market, by Product Type, 2024 - 2033 ($Million)
Table 21. Europe Vinca Alkaloid Compounds Market, by End-user, 2024 - 2033 ($Million)
Table 22. Germany Vinca Alkaloid Compounds Market, by Product Type, 2024 - 2033 ($Million)
Table 23. Germany Vinca Alkaloid Compounds Market, by End-user, 2024 - 2033 ($Million)
Table 24. France Vinca Alkaloid Compounds Market, by Product Type, 2024 - 2033 ($Million)
Table 25. France Vinca Alkaloid Compounds Market, by End-user, 2024 - 2033 ($Million)
Table 26. UK Vinca Alkaloid Compounds Market, by Product Type, 2024 - 2033 ($Million)
Table 27. UK Vinca Alkaloid Compounds Market, by End-user, 2024 - 2033 ($Million)
Table 28. Italy Vinca Alkaloid Compounds Market, by Product Type, 2024 - 2033 ($Million)
Table 29. Italy Vinca Alkaloid Compounds Market, by End-user, 2024 - 2033 ($Million)
Table 30. Spain Vinca Alkaloid Compounds Market, by Product Type, 2024 - 2033 ($Million)
Table 31. Spain Vinca Alkaloid Compounds Market, by End-user, 2024 - 2033 ($Million)
Table 32. Rest of Europe Vinca Alkaloid Compounds Market, by Product Type, 2024 - 2033 ($Million)
Table 33. Rest of Europe Vinca Alkaloid Compounds Market, by End-user, 2024 - 2033 ($Million)
Table 34. Asia-Pacific Vinca Alkaloid Compounds Market, by Country, 2024 - 2033 ($Million)
Table 35. Asia-Pacific Vinca Alkaloid Compounds Market, by Product Type, 2024 - 2033 ($Million)
Table 36. Asia-Pacific Vinca Alkaloid Compounds Market, by End-user, 2024 - 2033 ($Million)
Table 37. Japan Vinca Alkaloid Compounds Market, by Product Type, 2024 - 2033 ($Million)
Table 38. Japan Vinca Alkaloid Compounds Market, by End-user, 2024 - 2033 ($Million)
Table 39. China Vinca Alkaloid Compounds Market, by Product Type, 2024 - 2033 ($Million)
Table 40. China Vinca Alkaloid Compounds Market, by End-user, 2024 - 2033 ($Million)
Table 41. Australia Vinca Alkaloid Compounds Market, by Product Type, 2024 - 2033 ($Million)
Table 42. Australia Vinca Alkaloid Compounds Market, by End-user, 2024 - 2033 ($Million)
Table 43. India Vinca Alkaloid Compounds Market, by Product Type, 2024 - 2033 ($Million)
Table 44. India Vinca Alkaloid Compounds Market, by End-user, 2024 - 2033 ($Million)
Table 45. South Korea Vinca Alkaloid Compounds Market, by Product Type, 2024 - 2033 ($Million)
Table 46. South Korea Vinca Alkaloid Compounds Market, by End-user, 2024 - 2033 ($Million)
Table 47. Rest of Asia-Pacific Vinca Alkaloid Compounds Market, by Product Type, 2024 - 2033 ($Million)
Table 48. Rest of Asia-Pacific Vinca Alkaloid Compounds Market, by End-user, 2024 - 2033 ($Million)
Table 49. LAMEA Vinca Alkaloid Compounds Market, by Country, 2024 - 2033 ($Million)
Table 50. LAMEA Vinca Alkaloid Compounds Market, by Product Type, 2024 - 2033 ($Million)
Table 51. LAMEA Vinca Alkaloid Compounds Market, by End-user, 2024 - 2033 ($Million)
Table 52. Brazil Vinca Alkaloid Compounds Market, by Product Type, 2024 - 2033 ($Million)
Table 53. Brazil Vinca Alkaloid Compounds Market, by End-user, 2024 - 2033 ($Million)
Table 54. Saudi Arabia Vinca Alkaloid Compounds Market, by Product Type, 2024 - 2033 ($Million)
Table 55. Saudi Arabia Vinca Alkaloid Compounds Market, by End-user, 2024 - 2033 ($Million)
Table 56. South Africa Vinca Alkaloid Compounds Market, by Product Type, 2024 - 2033 ($Million)
Table 57. South Africa Vinca Alkaloid Compounds Market, by End-user, 2024 - 2033 ($Million)
Table 58. Rest of LAMEA Vinca Alkaloid Compounds Market, by Product Type, 2024 - 2033 ($Million)
Table 59. Rest of LAMEA Vinca Alkaloid Compounds Market, by End-user, 2024 - 2033 ($Million)
Table 60. Accord Healthcare Limited: Key Executives
Table 61. Accord Healthcare Limited: Company Snapshot
Table 62. Accord Healthcare Limited: Operating Segments
Table 63. Accord Healthcare Limited: Product Portfolio
Table 64. Accord Healthcare Limited: Key Strategic Moves and Developments
Table 65. Eli Lilly and Company.: Key Executives
Table 66. Eli Lilly and Company.: Company Snapshot
Table 67. Eli Lilly and Company.: Operating Segments
Table 68. Eli Lilly and Company.: Product Portfolio
Table 69. Eli Lilly and Company.: Key Strategic Moves and Developments
Table 70. Fresenius Kabi AG: Key Executives
Table 71. Fresenius Kabi AG: Company Snapshot
Table 72. Fresenius Kabi AG: Operating Segments
Table 73. Fresenius Kabi AG: Product Portfolio
Table 74. Fresenius Kabi AG: Key Strategic Moves and Developments
Table 75. Jiangsu Hansoh Pharmaceutical Group Co. Ltd.: Key Executives
Table 76. Jiangsu Hansoh Pharmaceutical Group Co. Ltd.: Company Snapshot
Table 77. Jiangsu Hansoh Pharmaceutical Group Co. Ltd.: Operating Segments
Table 78. Jiangsu Hansoh Pharmaceutical Group Co. Ltd.: Product Portfolio
Table 79. Jiangsu Hansoh Pharmaceutical Group Co. Ltd.: Key Strategic Moves and Developments
Table 80. Medline Industries, Lp.: Key Executives
Table 81. Medline Industries, Lp.: Company Snapshot
Table 82. Medline Industries, Lp.: Operating Segments
Table 83. Medline Industries, Lp.: Product Portfolio
Table 84. Medline Industries, Lp.: Key Strategic Moves and Developments
Table 85. Pfizer Inc.: Key Executives
Table 86. Pfizer Inc.: Company Snapshot
Table 87. Pfizer Inc.: Operating Segments
Table 88. Pfizer Inc.: Product Portfolio
Table 89. Pfizer Inc.: Key Strategic Moves and Developments
Table 90. Pierre Fabre S.A: Key Executives
Table 91. Pierre Fabre S.A: Company Snapshot
Table 92. Pierre Fabre S.A: Operating Segments
Table 93. Pierre Fabre S.A: Product Portfolio
Table 94. Pierre Fabre S.A: Key Strategic Moves and Developments
Table 95. Talon Pharmaceuticals: Key Executives
Table 96. Talon Pharmaceuticals: Company Snapshot
Table 97. Talon Pharmaceuticals: Operating Segments
Table 98. Talon Pharmaceuticals: Product Portfolio
Table 99. Talon Pharmaceuticals: Key Strategic Moves and Developments
Table 100. Teva Pharmaceutical Industries Limited: Key Executives
Table 101. Teva Pharmaceutical Industries Limited: Company Snapshot
Table 102. Teva Pharmaceutical Industries Limited: Operating Segments
Table 103. Teva Pharmaceutical Industries Limited: Product Portfolio
Table 104. Teva Pharmaceutical Industries Limited: Key Strategic Moves and Developments
Table 105. Viatris Inc.: Key Executives
Table 106. Viatris Inc.: Company Snapshot
Table 107. Viatris Inc.: Operating Segments
Table 108. Viatris Inc.: Product Portfolio
Table 109. Viatris Inc.: Key Strategic Moves and Developments
LIST OF FIGURES
Figure 1. Global Vinca Alkaloid Compounds Market, 2024 - 2033
Figure 2. Segmentation of Vinca Alkaloid Compounds Market, 2024 - 2033
Figure 3. Top Investment Pocket in Vinca Alkaloid Compounds Market
Figure 4. Moderate Bargaining Power of Buyers
Figure 5. Moderate Bargaining Power of Suppliers
Figure 6. Moderate Threat of New Entrants
Figure 7. Low Threat of Substitution
Figure 8. High Competitive Rivalry
Figure 9. Opportunities, Restraints and Drivers: Globalvinca Alkaloid Compounds Market
Figure 10. Global Vinca Alkaloid Compounds Market Segmentation, by Product Type
Figure 11. Vinca Alkaloid Compounds Market for Vinblastine, by Country, 2024 - 2033 ($Million)
Figure 12. Vinca Alkaloid Compounds Market for Vincristine, by Country, 2024 - 2033 ($Million)
Figure 13. Vinca Alkaloid Compounds Market for Vindesine, by Country, 2024 - 2033 ($Million)
Figure 14. Global Vinca Alkaloid Compounds Market Segmentation, by End-user
Figure 15. Vinca Alkaloid Compounds Market for Hospitals, by Country, 2024 - 2033 ($Million)
Figure 16. Vinca Alkaloid Compounds Market for Clinics, by Country, 2024 - 2033 ($Million)
Figure 17. Vinca Alkaloid Compounds Market for Academic Research Institutes, by Country, 2024 - 2033 ($Million)
Figure 18. Top Winning Strategies, by Year, 2021-2023*
Figure 19. Top Winning Strategies, by Development, 2021-2023*
Figure 20. Top Winning Strategies, by Company, 2021-2023*
Figure 21. Product Mapping of Top 10 Players
Figure 22. Competitive Dashboard
Figure 23. Competitive Heatmap: Vinca Alkaloid Compounds Market
Figure 24. Top Player Positioning, 2023
Figure 25. Accord Healthcare Limited: Net Sales, 2021-2023 ($Million)
Figure 26. Accord Healthcare Limited: Revenue Share, by Segment, 2023 (%)
Figure 27. Accord Healthcare Limited: Revenue Share, by Region, 2023 (%)
Figure 28. Eli Lilly and Company.: Net Sales, 2021-2023 ($Million)
Figure 29. Eli Lilly and Company.: Revenue Share, by Segment, 2023 (%)
Figure 30. Eli Lilly and Company.: Revenue Share, by Region, 2023 (%)
Figure 31. Fresenius Kabi AG: Net Sales, 2021-2023 ($Million)
Figure 32. Fresenius Kabi AG: Revenue Share, by Segment, 2023 (%)
Figure 33. Fresenius Kabi AG: Revenue Share, by Region, 2023 (%)
Figure 34. Jiangsu Hansoh Pharmaceutical Group Co. Ltd.: Net Sales, 2021-2023 ($Million)
Figure 35. Jiangsu Hansoh Pharmaceutical Group Co. Ltd.: Revenue Share, by Segment, 2023 (%)
Figure 36. Jiangsu Hansoh Pharmaceutical Group Co. Ltd.: Revenue Share, by Region, 2023 (%)
Figure 37. Medline Industries, Lp.: Net Sales, 2021-2023 ($Million)
Figure 38. Medline Industries, Lp.: Revenue Share, by Segment, 2023 (%)
Figure 39. Medline Industries, Lp.: Revenue Share, by Region, 2023 (%)
Figure 40. Pfizer Inc.: Net Sales, 2021-2023 ($Million)
Figure 41. Pfizer Inc.: Revenue Share, by Segment, 2023 (%)
Figure 42. Pfizer Inc.: Revenue Share, by Region, 2023 (%)
Figure 43. Pierre Fabre S.A: Net Sales, 2021-2023 ($Million)
Figure 44. Pierre Fabre S.A: Revenue Share, by Segment, 2023 (%)
Figure 45. Pierre Fabre S.A: Revenue Share, by Region, 2023 (%)
Figure 46. Talon Pharmaceuticals: Net Sales, 2021-2023 ($Million)
Figure 47. Talon Pharmaceuticals: Revenue Share, by Segment, 2023 (%)
Figure 48. Talon Pharmaceuticals: Revenue Share, by Region, 2023 (%)
Figure 49. Teva Pharmaceutical Industries Limited: Net Sales, 2021-2023 ($Million)
Figure 50. Teva Pharmaceutical Industries Limited: Revenue Share, by Segment, 2023 (%)
Figure 51. Teva Pharmaceutical Industries Limited: Revenue Share, by Region, 2023 (%)
Figure 52. Viatris Inc.: Net Sales, 2021-2023 ($Million)
Figure 53. Viatris Inc.: Revenue Share, by Segment, 2023 (%)
Figure 54. Viatris Inc.: Revenue Share, by Region, 2023 (%)

Companies Mentioned

Key Market Players in the Vinca Alkaloid Compounds Market include:
  • Accord Healthcare Limited
  • Eli Lilly and Company.
  • Fresenius Kabi AG
  • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  • Medline Industries, LP.
  • Pfizer Inc.
  • Pierre Fabre S.A
  • Talon Pharmaceuticals
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages280
PublishedJuly 2024
Forecast Period2023 - 2033
Estimated Market Value ( USD ) in 2023 $ 81 million
Forecasted Market Value ( USD ) by 2033 $ 161.5 million
Compound Annual Growth Rate7.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Vinca Alkaloid Compounds Market by Product, End User - Global Forecast 2025-2030 - Product Image

Vinca Alkaloid Compounds Market by Product, End User - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Vinca Alkaloid Compounds Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, and Product Type - Product Image

Vinca Alkaloid Compounds Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, and Product Type

  • Report
  • 95 Pages
  • Global
From
New Strategies Targeting Cancer Metabolism. Anticancer Drugs, Synthetic Analogues and Antitumor Agents - Product Image

New Strategies Targeting Cancer Metabolism. Anticancer Drugs, Synthetic Analogues and Antitumor Agents

  • Book
Chemotherapy Market by Type, Drug Class, Therapy Type, Application, Route of Administration, End User - Global Forecast 2025-2030 - Product Image

Chemotherapy Market by Type, Drug Class, Therapy Type, Application, Route of Administration, End User - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
Key Heterocyclic Cores for Smart Anticancer Drug-Design Part II - Product Image

Key Heterocyclic Cores for Smart Anticancer Drug-Design Part II

  • Book
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.